BUZZ-Street View: Late-stage data awaited to gauge Amgen's weight-loss drug

Reuters01-13
BUZZ-Street View: Late-stage data awaited to gauge Amgen's weight-loss drug

** An extension study of Amgen's AMGN.O experimental obesity drug MariTide found that it helped people maintain weight loss when given at a lower dose or less frequently, the company said on Monday

** At least one analyst raised price target on Amgen (BMO to $372), ratings maintained at "neutral" or "market perform" ratings

STREET AWAITS LATE-STAGE DATA

** Citi ("Neutral", PT $315) says looking "for additional data to further quantify and contextualize the responses seen from the trials into the broader GLP-1 landscape"

** Leerink Partners ("Market Perform") notes limited MariTide results disclosures with no figures, says "overall, these results are expected to inform the MariTide development strategy"

** JPMorgan ("Neutral") says "we will need to see late-stage data to more accurately gauge Maritide's competitive positioning, especially given the number of other monthly dosed assets advancing in the space"

** BMO ("Outperform", PT $372) says "await detailed data to better understand the profile"

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment